Browse News
Filter News
Found 12 articles
-
Dutch biotech Xinvento raises seed round to develop a treatment for the rare disease Congenital Hyperinsulinism
4/21/2022
Xinvento, a biotech company aiming to improve the lives of those with Congenital Hyperinsulinism, announces the completion of a seed funding round.
-
72% of employers are currently experiencing a decrease in the volume of candidates applying to their jobs.
-
Money on the Move: January 19 – 25
1/26/2022
Temps are falling and so is investor cash. Here's which biotech companies are scooping up the dollars this week. -
Leyden Labs secured $140 million in a Series B financing round. Combined with $40 million from a Series A round in March 2021, the company has significant funding to advance its portfolio of candidates.
-
Leyden Labs Raises $200M in 2021 for a New Approach to Combat Viruses
1/25/2022
Leyden Laboratories B.V., (the "Company" or "Leyden Labs") today announced closing a $140M Series B financing, bringing its total capital raised to approximately $200M in 2021.
-
Leyden Labs Licenses Pan-Influenza Antibody from Janssen
1/18/2022
Leyden Laboratories B.V., announces the development of an intranasal spray protecting against influenza A and influenza B based on the human monoclonal antibody CR9114.
-
Nanopharm and Leyden Labs Announce Agreement to Develop Intranasal Spray Product Candidates for Prophylactic Use Against Known and New Respiratory Viruses
7/21/2021
Nanopharm Ltd., and Leyden Labs, today announced that they have entered into an agreement to develop nasal sprays that may provide broad protection against respiratory viruses, combining Leyden Labs’ portfolio and Nanopharm’s expertise in the development of nasally delivered drug products.
-
According to Teo, the definition of the next pandemic depends a lot on one’s perspective.
-
Money on the Move: March 24-30
3/31/2021
Over $700 million dropped into IPO biotech stock this week, with hundreds of millions more pouring into company financing rounds. Here are some of the top earners this past week. -
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Leyden Labs to Unlock a New Generation of Preventative Medicines against Known and Future Viruses by Securing a €40 Million Series A from GV (formerly Google Ventures), F-Prime and Casdin Capital
3/25/2021
Funding to advance platform and portfolio of intranasal products that protect against a broad range of respiratory viruses, including influenza and coronaviruses, to let people live their lives freely
-
CorTechs Labs Reveals Enhanced NeuroQuant Features at RSNA 2018
11/20/2018
NeuroQuant® 3.0 introduces advanced features for enhanced results and improved customer experience